NCT00463203View on ClinicalTrials.gov

Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

March 31, 2011

Study Completion Date

June 30, 2011

Conditions
Brain NeoplasmsGlioma
Interventions
DRUG

Bevacizumab

10 mg/kg every 2 weeks

DRUG

Irinotecan

125 mg/m2 non-EIAED or 340 mg/m2 EIAED every 2 weeks

Trial Locations (3)

2100

Rigshospitalet, Copenhagen

5000

Odense University Hospital, Odense

9000

Aalborg University Hospital, Aalborg

All Listed Sponsors
lead

Rigshospitalet, Denmark

OTHER

NCT00463203 - Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy | Biotech Hunter | Biotech Hunter